Skip to content

Clinical trials

Triple Negative Breast Neoplasms trials in the Netherlands

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Triple Negative Breast Neoplasms Country / region: Netherlands Clear all

32 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20112
20141
20152
20161
20177
20183
20191
20213
20224
20232
20242
20254

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Recruiting8
Active, not recruiting6
Terminated4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals6
Merck Sharp & Dohme LLC3
AstraZeneca2
Bristol-Myers Squibb2
Exelixis2
Gilead Sciences2
The Netherlands Cancer Institute2
AbbVie1
Amgen1
Array Biopharma, now a wholly owned subsidiary of Pfizer1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Triple Negative Breast Neoplasms32
Carcinoma, Non-Small-Cell Lung13
Breast Neoplasms7
Pancreatic Neoplasms6
Colorectal Neoplasms5
Endometrial Neoplasms5
Neoplasms5
Ovarian Neoplasms5
Head and Neck Neoplasms4
Melanoma4

Trials

Showing 51 to 32 of 32. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.